山东大学学报(医学版) ›› 2016, Vol. 54 ›› Issue (10): 55-59.doi: 10.6040/j.issn.1671-7554.0.2015.1101
满琦1,张安1,张源2,樊明德1,马道新3,王成伟1
MAN Qi1, ZHANG An1, ZHANG Yuan2, FAN Mingde1, MA Daoxin3, WANG Chengwei1
摘要: 目的 探究脑胶质瘤患者外周血中Th17、Th22细胞的表达及意义。 方法 取34例脑胶质瘤患者及24例健康对照者为研究对象,用流式细胞术检测外周血中Th17、Th22细胞的表达比例。用实时荧光定量逆转录聚合酶链反应(RT-PCR)技术检测外周血单个核细胞中视黄酸相关孤儿核受体(RORC)mRNA及芳香烃受体(AHR)mRNA的表达。用酶联免疫吸附分析(ELISA)检测血浆中Th22细胞相关因子白细胞介素-22(IL-22)的水平。 结果 与健康对照组相比,脑胶质瘤患者外周血Th17细胞比例(占淋巴细胞)升高不明显(P>0.05),且高级别组(WHO Ⅲ-Ⅳ级)与低级别组(WHO Ⅰ-Ⅱ级)之间差异不明显(P>0.05);Th22细胞比例(占淋巴细胞)明显升高(P<0.05),且不同级别之间差异明显(P<0.05)。脑胶质瘤患者Th17与Th22细胞呈正相关(r=0.40, P=0.03),健康对照组中二者无相关(P>0.05)。与健康对照组比较,患者外周血中RORC mRNA及AHR mRNA的升高不明显(P>0.05, P>0.05),且不同级别间差异不明显(P>0.05, P>0.05)。患者血浆IL-22水平比健康对照组明显升高(P<0.05),但不同级别之间差异不明显(P>0.05)。 结论 脑胶质瘤患者外周血中存在Th22细胞及IL-22异常升高,Th17细胞与Th22细胞可能共同参与胶质瘤的发生发展过程。
中图分类号:
[1] Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011[J]. Neuro Oncol, 2014, 16(Suppl 4): iv1-iv63. [2] Rolle CE, Sengupta S, Lesniak MS. Challenges in clinical design of immunotherapy trials for malignant glioma[J]. Neurosurg Clin N Am, 2010, 21(1): 201-214. [3] Galea I, Bernardes-Silva M, Forse PA, et al. An antigen-specific pathway for CD8 T cells across the blood-brain barrier[J]. J Exp Med, 2007, 204(9): 2023-2030. [4] Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type1 and 2 lineages[J]. Nat Immunol, 2005, 6(11): 1123-1132. [5] Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells[J]. Cell, 2006, 126(6): 1121-1133. [6] Trifari S, Kaplan CD, Tran EH, et al. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells[J]. Nat Immunol, 2009, 10(8): 864-871. [7] Duhen T, Geiger R, Jarrossay D, et al. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells[J]. Nat Immunol, 2009, 10(8): 857-863. [8] Muranski P, Boni A, Antony PA, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma[J]. Blood, 2008, 112(2): 362-373. [9] Wang L, Yi T, Kortylewski M, et al. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway[J]. J Exp Med, 2009, 206(7): 1457-1464. [10] Wainwright DA, Sengupta S, Han Y, et al. The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human glioma[J]. PLoS One, 2010, 5(10): e15390. doi: 10.1371/journal.pone.0015390. [11] Hu J, Mao Y, Li M, et al. The profile of Th17 subset in glioma[J]. Int Immunopharmacol, 2011, 11(9): 1173-1179. [12] Wolk K, Witte E, Witte K, et al. Biology of interleukin-22[J]. Semin Immunopathol, 2010, 32(1):17-31. [13] Zenewicz LA, Yancopoulos GD, Valenzuela DM, et al. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation[J]. Immunity, 2007, 27(4): 647-659. [14] Dumoutier L, Louahed J, Renauld JC. Cloning and characterization of IL-10-related T cell-derived inducible factor(IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9[J]. J Immunol, 2000, 164(4):1814-1819. [15] Zenewicz LA, Flavell RA. Recent advances in IL-22 biology[J]. Int Immunol, 2011, 23(3):159-163. [16] Witte E, Witte K, Warszawska K, et al. Interleukin-22: a cytokine produced by T, NK and NKT cell subsets, with importance in the innate immune defense and tissue protection[J]. Cytokine Growth Factor Rev, 2010, 21(5): 365-379. [17] Xie MH, Aggarwal S, Ho WH, et al. Interleukin(IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R[J]. J Biol Chem, 2000, 275(40): 31335-31339. [18] Akil H, Abbaci A, Lalloue F, et al. IL22/IL-22R pathway induces cell survival in human glioblastoma cells[J]. PLoS One, 2015, 10(3): e0119872. doi: 10.1371/journal.pone.0119872. |
[1] | 董晓婧,李静,赵蕾,齐眉,孙泽雨,王红,赵蔚明. 鼠衣原体肺部感染中自然杀伤细胞对白细胞介素-22产生及疾病进程的影响[J]. 山东大学学报(医学版), 2016, 54(11): 19-23. |
[2] | 田馨莉, 矫俊, 张腾, 马道新, 崔保霞. Th22细胞联合Th17细胞在宫颈癌外周血中的表达及意义[J]. 山东大学学报(医学版), 2015, 53(7): 43-47. |
[3] | 白金霞, 白金运, 石秀菊, 许洪伟. IL-22介导的STAT3信号通路对急性重症胰腺炎小鼠的保护作用[J]. 山东大学学报(医学版), 2015, 53(6): 1-6. |
[4] | 张荣军, 韩波, 高聆, 朱梅, 丁国玉, 梁燕. siRNA沉默CD40基因对实验性自身免疫性心肌炎大鼠的作用及IL-22表达的影响[J]. 山东大学学报(医学版), 2015, 53(5): 36-40. |
[5] | 范恒建,张玉可,肖伟,张一,李海军,王得翔 . 肺腺癌患者外周血Treg和Th17细胞的变化及其对预后的影响[J]. 山东大学学报(医学版), 2012, 50(9): 73-78. |
[6] | 郑鲲鹏1,宋辉2,樊明德1,张源3,李科1,王成伟1. h17细胞相关因子在人脑胶质瘤中的测定[J]. 山东大学学报(医学版), 2012, 50(6): 87-91. |
[7] | 尹萌,戚向敏,颜士果,魏美荣,陈丹,宋京,张达. Th17细胞在口腔扁平苔藓中的作用[J]. 山东大学学报(医学版), 2012, 50(12): 114-. |
[8] | 刘香岚,姜杨,王群,朱法良,董兆静,郭春,张利宁. PDCD4 基因对T淋巴细胞亚群分化的影响[J]. 山东大学学报(医学版), 2012, 50(11): 6-. |
[9] | 陈璇,王玉. Vogt-小柳原田病患者外周血Th17细胞的变化及意义[J]. 山东大学学报(医学版), 2011, 49(9): 153-. |
[10] | 李海军,肖伟. 肺腺癌患者外周血Th17细胞比例变化及临床意义[J]. 山东大学学报(医学版), 2011, 49(8): 108-112. |
[11] | 李娜,边红军,张娟,季晓平. 慢性心力衰竭患者外周血中Th17及Treg细胞的检测及意义[J]. 山东大学学报(医学版), 2010, 48(6): 100-103. |
|